Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
Technology appraisal guidance
Reference number: TA947
Published:
Evidence
Review and download supporting evidence. Includes the full guideline if available.